Cantor Fitzgerald Maintains Overweight on AVITA Medical, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has maintained an Overweight rating on AVITA Medical (NASDAQ:RCEL) and increased the price target from $20 to $22.
January 19, 2024 | 3:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Ross Osborn maintains an Overweight rating on AVITA Medical and raises the price target from $20 to $22.
The increase in price target by a reputable analyst typically signals a positive outlook on the company's future performance and can lead to increased investor confidence. As a result, the stock price may experience upward pressure in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100